Skip to main content

Breast Cancer Chemosensitivity

  • Book
  • © 2007

Overview

  • A useful reference to some of the most important aspects of systemic therapy resistance
  • Allows those who are interested in breast cancer therapy to get a jump-start on critical issues in breast cancer therapeutic resistance

Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 608)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (11 chapters)

Keywords

About this book

In Breast Cancer Chemosensitivity, a group of world leading experts review critical aspects of resistance to systemic therapy in breast cancer patients. Beginning with a clinical overview of the problem Breast Cancer Chemosensitivity moves on to focus on the latest findings of molecular mechanisms of drug resistance. These include in-depth discussions on multidrug resistance by P-glycoprotein and the multidrug resistance protein family, resistance to therapeutic agent-induced apoptosis, cell cycle deregulation, deregulation of DNA repair, loss of tumor suppressor genes, integrin-mediated adhesion, insulin-like growth factors, epidermal growth factor, and ErbB2 in modulating breast cancer response to systemic therapy, especially, certain chemotherapeutic agents. Breast Cancer Chemosensitivity provides an example of using novel approaches for chemosensitization of breast cancer cells that gives readers an idea about the future direction in breast cancer treatment.

Editors and Affiliations

  • Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, USA

    Dihua Yu

  • Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, USA

    Mien-Chie Hung

Bibliographic Information

Publish with us